Marie Hospitel

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

Anas Gazzah, Philippe L. Bédard, Cinta Hierro et al. · Annals of Oncology · 2022 · 81 citations

Pharmacy, Oncology, Pharmacology +17

Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

Cristiana Sessa, Patricia LoRusso, Anthony W. Tolcher et al. · Clinical Cancer Research · 2013 · 46 citations

Medicine, Oncology, Pharmacology +17

Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).

Anas Gazzah, Charles Ricordel, Sophie Cousin et al. · Journal of Clinical Oncology · 2020 · 38 citations

Medicine, Oncology, Pharmacology +17

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

Ferry A.L.M. Eskens, Patricia Tresca, Diégo Tosi et al. · British Journal of Cancer · 2014 · 36 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors

Rastislav Bahleda, Cristiana Sessa, Gianluca Del Conte et al. · Investigational New Drugs · 2014 · 24 citations

Medicine, Pharmacokinetics, Pharmacology +13